Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Income from Continuing Operations: 2020-2025

Historic Income from Continuing Operations for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $2.9 million.

  • Mirum Pharmaceuticals' Income from Continuing Operations rose 120.41% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.4 million, marking a year-over-year increase of 58.50%. This contributed to the annual value of -$87.9 million for FY2024, which is 46.18% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Income from Continuing Operations is $2.9 million, which was up 149.56% from -$5.9 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Income from Continuing Operations' 5-year high stood at $57.3 million during Q4 2021, with a 5-year trough of -$74.0 million in Q2 2023.
  • Over the past 3 years, Mirum Pharmaceuticals' median Income from Continuing Operations value was -$23.8 million (recorded in 2024), while the average stood at -$24.5 million.
  • In the last 5 years, Mirum Pharmaceuticals' Income from Continuing Operations surged by 253.52% in 2021 and then tumbled by 175.01% in 2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Income from Continuing Operations (Quarterly) stood at $57.3 million in 2021, then slumped by 163.60% to -$36.4 million in 2022, then rose by 2.12% to -$35.7 million in 2023, then skyrocketed by 33.28% to -$23.8 million in 2024, then skyrocketed by 120.41% to $2.9 million in 2025.
  • Its Income from Continuing Operations was $2.9 million in Q3 2025, compared to -$5.9 million in Q2 2025 and -$14.7 million in Q1 2025.